Avoro Capital Advisors LLC boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 9.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,111,111 shares of the biopharmaceutical company’s stock after purchasing an additional 100,000 shares during the period. […]
Avoro Capital Advisors LLC grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 9.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,111,111 shares of the biopharmaceutical company’s stock after purchasing an additional 100,000 shares during the quarter. Alnylam […]
Capital Research Global Investors grew its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 5.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,930,079 shares of the biopharmaceutical company’s stock after buying an additional 146,236 shares during […]
Rhenman & Partners Asset Management AB decreased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 16.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 37,500 shares of the biopharmaceutical company’s stock after selling 7,500 […]
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) Director Amy W. Schulman sold 21,700 shares of Alnylam Pharmaceuticals stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total value of $3,224,620.00. Following the transaction, the director now directly owns 8,436 shares of the company’s […]